TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ConvaTec ( (GB:CTEC) ) has provided an announcement.
Convatec Group Plc announced its total voting rights as of November 30, 2025, with an issued share capital comprising over 2 billion ordinary shares, of which approximately 1.96 billion carry voting rights. The company also noted that shares purchased under a buyback program are in the settlement process and will be held in treasury. This update is relevant for shareholders to determine their notification obligations under the FCA’s rules.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £3.25 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Outperform.
ConvaTec’s overall stock score is driven primarily by its strong financial performance, characterized by consistent revenue growth and solid profitability. Technical analysis indicates a moderate upward trend, although valuation metrics suggest the stock may be overvalued. The absence of earnings call insights and corporate events limits additional context.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
Convatec is a global medical products and technologies company specializing in solutions for chronic condition management. It holds leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care, operating in around 90 countries with revenues exceeding $2 billion in 2024. Convatec is a FTSE 100 Index constituent.
Average Trading Volume: 9,406,962
Technical Sentiment Signal: Hold
Current Market Cap: £4.61B
For a thorough assessment of CTEC stock, go to TipRanks’ Stock Analysis page.